Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
Want to see ADPT full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrays a company with strong, broad-based MRD momentum: double-digit revenue growth, volume records, margin expansion, a raised MRD revenue guide, growing backlog, and improving MRD profitability. Challenges are concentrated in the immune medicine business (declining revenue and losses), company-level net loss and elevated operating expenses, milestone lumpiness, and reimbursement/regulatory uncertainty. Taken together the positives—notably durable clinical adoption, pricing gains, margin improvement, a large and growing backlog, and a solid cash position—outweigh the negatives, which are largely isolated or acknowledged with mitigations in progress.Company Guidance
Strong Top-Line Growth
Total revenue of $70.9M, up 45% year over year, driven primarily by MRD which accounted for ~95% of revenue.
MRD Revenue and Guidance Raise
MRD revenue grew 53% YoY to $67.1M. Full-year MRD revenue guidance raised to $260M–$270M (previously $255M–$265M); midpoint implies ~25% YoY growth (33% excluding milestones).
Clinical Volume and clonoSEQ Adoption
clonoSEQ clinical volumes up 41% YoY; Q1 tests ~32,600 (up 9% sequentially). Clinical business revenue up 54% YoY. Ordering clinicians grew 43% YoY to nearly 5,000.
Community and Blood-Based Testing Momentum
Community volumes grew 67% YoY and now represent 35% of total testing. Blood-based testing reached 49% of MRD volume; in multiple myeloma blood-based share rose to 29% (up 8 percentage points YoY).
Pricing and Reimbursement Gains
U.S. ASP increased 11% YoY to $1,360 per test. clonoSEQ added to Texas Medicaid policy manual (one of two tests listed) with up to six tests/year, and 10 commercial payer agreements signed in Q1.
Margin Expansion and Sequencing Efficiency
Sequencing gross margin improved 8 percentage points YoY to 70%, driven by NovaSeq X efficiencies, scale, and favorable pricing; company targeting >70% and a long-term north star ~75%.
Improved Segment Profitability and Backlog
MRD adjusted EBITDA of $12.1M versus a loss of $4.1M prior year. Pharma bookings/backlog ~ $254M, up 24% YoY, and ~190 active studies (111 primary/secondary; 23 primary).
Cash Position and Discipline
Ended quarter with approximately $222M in cash and operating plan to keep cash burn in the $15M–$20M range for 2026 while targeting positive adjusted EBITDA and free cash flow for the full company in 2026.
Immune Medicine Data and Partnerships
Proprietary immune dataset exceeding 6 million functional TCR–antigen pairs across ~50,000 antigens and 50+ HLA types; digital AI model outperformed public benchmarks. New RA target-discovery partnership with Pfizer (1,000+ patient samples).
Operational Execution: EMR Integrations & Repeat Utilization
Six new Epic accounts added YTD; seven of top-10 accounts fully integrated. Flatiron-enabled serial monitoring delivering strong pull-through with 72% of repeat orders due being fulfilled.
ADPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $13.78 | $14.43 | +4.72% |
Feb 05, 2026 | $16.47 | $15.77 | -4.25% |
Nov 05, 2025 | $17.59 | $15.56 | -11.54% |
Aug 05, 2025 | $11.05 | $11.69 | +5.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Adaptive Biotechnologies Corp (ADPT) report earnings?
Adaptive Biotechnologies Corp (ADPT) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Adaptive Biotechnologies Corp (ADPT) earnings time?
Adaptive Biotechnologies Corp (ADPT) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADPT EPS forecast?
ADPT EPS forecast for the fiscal quarter 2026 (Q2) is -0.14.